LX-1001

N/A

Report date: 2024/10/18 17:38:25

Base Information

Drug NameLX-1001
Drug Alias NameAAVrh.10hAPOE2LX-1001
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAVrh10 vector
Mechanisms of ActionApolipoprotein E2 gene transference
TargetsApolipoprotein E2
Therapy Area/IndicationsAlzheimer Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesLEXEO Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesLexeo Therapeutics IncLEXEO Therapeutics
Inactive CompaniesN/A
Active IndicationsAlzheimer Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A